Section 36-2511 - NomenclatureThe controlled substances listed or to be listed in the schedules in sections 36-2512, 36-2513, 36-2514, 36-2515, 36-2516, 36-2517and 36-2517.01 or the rules adopted pursuant to this article are included by whatever official, common, usual, chemical or trade name designated.
Amended by L. 2023, ch. 97,s. 1, eff. if, on or before January 1, 2026 a 3, 4-methylenedioxymethamphetamine investigational product is newly approved as a prescription medication pursuant to 21 U.S.C. 355 and is controlled under a federal interim final rule issued pursuant to 21 U.S.C. 811(j) and published in the Federal Register.Amended by L. 2021, ch. 61,s. 12, eff. 9/29/2021.Amended by L. 2017, ch. 188,s. 1, eff. contingent upon federal approval of a cannabidiol investigational product on or before 1/1/2020.